Yellow fever vaccine seroconversion in travelers.

Authors:
Address: Mount Auburn Hospital, Cambridge, Massachusetts, USA. allison.h.kay@gmail.com
Journal:

Publication:

abstract

To assess immunity after Yellow fever (YF) 17D live-attenuated vaccination, we measured the antibody levels before vaccination and at 21 days and 8 months after vaccination in YF-naïve travelers. Thirty subjects were enrolled in the study, with 100% providing sera at 21 days and 86.6% providing sera at 8 months. All subjects seroconverted by day 21, and the geometric mean titers of the anti-YF antibodies decreased between day 21 and month 8 from 6,451 to 1,246. This study corroborates the high rates of seroconversion achieved by the live-attenuated YF vaccine.

Related Articles
Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Hum Vaccin. 2010
Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M. Hum Vaccin. 2010 Nov; 6(11):906-14. Epub 2010 Nov 1.
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Hum Vaccin. 2006
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, et al. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7. Epub 2006 Mar 15.
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
Vaccine. 2002
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.
Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, et al. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
Review Yellow fever vaccine: past, present and future.
Expert Opin Biol Ther. 2008
Review Yellow fever vaccine: past, present and future.
Roukens AH, Visser LG. Expert Opin Biol Ther. 2008 Nov; 8(11):1787-95.
Review Prevention of yellow fever in persons traveling to the tropics.
Clin Infect Dis. 2002
Review Prevention of yellow fever in persons traveling to the tropics.
Monath TP, Cetron MS. Clin Infect Dis. 2002 May 15; 34(10):1369-78. Epub 2002 Apr 25.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.